EUVIMEDEUVIMED entdecken
Open Access

Engineered probiotics for tumor-targeted combination chemoimmunotherapy

Zaofeng Yang iD, Jongwon Im iD, Noah Chen iD, Dylan L Mariuzza iD, Kenia de Los Santos-Alexis iD, Fangda Li iD, Edward R Ballister iD, Olivia R Ringham, Tal Danino iD, Nicholas Arpaia iD

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.ady2289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Zaofeng Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Immunotherapy, Probiotics, Neoplasms. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achieving tumor-specific delivery and sustained activation of both cytotoxic and immune-modulating agents remains a critical challenge in chemoimmunotherapy. Here, a bacterial platform was engineered to combine enzyme/prodrug chemotherapy with immunotherapy, in which tumor-homing Escherichia coli Nissle 1917 expressed cytosine deaminase to convert the prodrug 5-fluorocytosine into the cytotoxic drug 5-fluorouracil and concurrently produced an IL-15 superagonist and a PD-L1 blocking nanobody in tumors. This platform demonstrated potent antitumor effects in murine MC38 and B16-F10 solid tumor models. Mechanistic analyses showed that bacterial enzyme/prodrug therapy alone elicited both immune activation and compensatory immunosuppressive responses, whereas inclusion of IL-15 superagonist and PD-L1 blockade enhanced activation of antigen-presenting cells, T cells, and natural killer cells and attenuated immunosuppressive pathways. Abscopal and rechallenge experiments indicated that this bacterial chemoimmunotherapy strategy induces systemic antitumor immunity and durable immune memory. In summary, our approach integrates enzyme/prodrug therapy and immunotherapy into a single bacterial delivery system, overcoming key limitations of conventional therapies by providing a rationally designed framework for spatially controlled chemoimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyProbioticsNeoplasmsAnimalsMiceProdrugsCell Line, TumorEscherichia coliCytosine DeaminaseMice, Inbred C57BLFlucytosineInterleukin-15FluorouracilHumans

Substanzen

ProdrugsCytosine DeaminaseFlucytosineInterleukin-15Fluorouracil

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.
  • Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
  • Data Science Institute, Columbia University, New York, NY 100270027, USA.

ORCID-Profile: Zaofeng Yang, Jongwon Im, Noah Chen, Dylan L Mariuzza, Kenia de Los Santos-Alexis, Fangda Li, Edward R Ballister, Tal Danino, Nicholas Arpaia

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Yang, Z., Im, J., Chen, N., Mariuzza, D. L., de Los Santos-Alexis, K., Li, F., Ballister, E. R., Ringham, O. R., Danino, T., & Arpaia, N. (2026). Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ady2289

Vancouver

Yang Z, Im J, Chen N, Mariuzza DL, de Los Santos-Alexis K, Li F, et al. Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.ady2289

BibTeX
@article{Yang2026,
  author = {Yang, Zaofeng and Im, Jongwon and Chen, Noah and Mariuzza, Dylan L and de Los Santos-Alexis, Kenia and Li, Fangda and Ballister, Edward R and Ringham, Olivia R and Danino, Tal and Arpaia, Nicholas},
  title = {Engineered probiotics for tumor-targeted combination chemoimmunotherapy},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.ady2289}
}
Kostenlos starten →